Medical treatment with targeted therapy for metastatic urothelial bladder carcinoma

Targeted therapeutic strategies are becoming a reality for patients with urothelial carcinoma. An FGFR inhibitor and an antibody drug conjugate gained FDA approval in 2019. In addition, there are other ongoing efforts to characterize distinct molecular subtypes of urothelial carcinoma (UC) that contain targetable genomic alterations. The future will see more studies to identify new targets, biomarkers of response, and mechanisms of resistance, thus leading to continued expansion of our strategies against UC. Here, we summarize the prominent strategies in targeted therapy for advanced-stage UC.